IgG subclass antibodies to human and bacterial HSP60 are not associated with disease activity and progression over time in axial spondyloarthritis by Carlsen, Thomas Gelsing et al.
RESEARCH ARTICLE Open Access
IgG subclass antibodies to human and bacterial
HSP60 are not associated with disease activity and
progression over time in axial spondyloarthritis
Thomas Gelsing Carlsen1*, Astrid Hjelholt2, Anne Grethe Jurik3, Berit Schiøttz-Christensen4, Anna Zejden3,
Gunna Christiansen2,6, Bent Deleuran2,5 and Svend Birkelund1,6
Abstract
Introduction: Spondyloarthritis (SpA), an interrelated group of rheumatic diseases, has been suggested to be
triggered by bacterial infections prior to the development of an autoimmune response that causes inflammation of
the spinal and peripheral joints. Because human heat shock protein 60 (HSP60), recently renamed HSPD1, and
bacterial HSP60 are highly homologous, immunological cross-reactivity has been proposed as a mechanism of
disease initiation. However, previous investigations of the humoral immune response to HSP60 in SpA patients
have lacked determination of immunoglobulin G (IgG) subclasses and patient follow-up. In this study, we have
focused on these parameters in a cohort of axial SpA patients with a well-established set of clinical characteristics,
including MRI changes and human leukocyte antigen B27.
Methods: IgG subclass antibodies (IgG1, IgG2, IgG3 and IgG4) against recombinant HSP60 of three reactive
arthritis-related bacteria; human HSP60; and the microorganisms Chlamydia trachomatis and C. pneumoniae were
determined by ELISA. Serum samples collected from 2004 to 2006 and in 2010 and 2011 from 39 axial SpA
patients were analyzed and compared with samples from 39 healthy controls. The Mann-Whitney U test and
Wilcoxon matched pairs test were used to compare the antibody levels in different and paired groups, respectively.
P < 0.01 was considered significant. The Spearman nonparametric correlation was used to determine correlation
between antibody levels and between antibody levels and the disease parameters.
Results: Elevated levels of IgG1 and IgG3 to human HSP60 and IgG1 to HSP60 of Salmonella enterica Enteritidis
were observed in SpA patients compared with healthy controls at both time points. The antibody levels were
almost constant over time for IgG1, whereas high levels of IgG3 to human HSP60 tended to decrease over time.
The antibody response to human HSP60 was predominantly of the IgG3 subclass, and patients with high levels of
IgG3 to this antigen had low levels of IgG1, indicating an inverse association. Different IgG subclasses were
produced against bacterial and human HSP60 in the same serum sample, IgG1 and IgG3, respectively, indicating
that there was no cross-reaction.
Conclusions: A significant association was observed between axial SpA and the presence of IgG1/IgG3 antibodies
to human HSP60 and of IgG1 to S. enterica Enteritidis and C. trachomatis. Generation of antibodies to human
HSP60 was independent of the presence of antibodies to bacterial HSP60. No association was observed between
clinical and MRI changes with antibodies over time. Altogether, such antibodies do not reflect the disease activity
in these patients.
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Introduction
For more than two decades, heat shock proteins (HSPs)
have been known for their phylogenetically conserved
composition and immune-modulating activities [1].
They are ubiquitous in cellular life and exist in both
eukaryotic and prokaryotic cells, where their major role
is to act as molecular chaperones. Over the past few
years, it has become evident that, in addition to their
function as intracellular chaperones, HSPs are also
found in the cell membrane and outside the cell, pre-
sumably acting as indicators of the stress conditions and
activating other cells, particularly cells of the immune
system [2]. As a response to stress conditions, their
expression level is increased to prevent aggregation of
misfolded proteins [3]. Such conditions are prevalent
during intracellular bacterial infections, where the highly
conserved HSPs from the 60 kDa family (HSP60; also
known as GroEL) act as potent stimulators of both the
innate and adaptive immune systems [4].
Some rheumatic diseases, such as reactive arthritis (ReA)
and Lyme disease, are associated with bacterial infections.
In connection with this, it has been suggested that bac-
teria-related autoimmunity may be an important factor in
the etiology of such diseases [5]. One hypothesis to explain
the pathogenic mechanism after a bacterial infection is
molecular mimicry, that is, sharing of linear or conforma-
tional epitopes common to microbial antigens and host
cell molecules, giving rise to an inappropriate immune
response [6]. Human HSP60, recently renamed HSPD1 in
a proposed new nomenclature [7], shares more than 50%
of its sequence with bacterial HSP60, and, consequently,
antibody and T-cell recognition of human HSP60 have
been investigated extensively in a number of studies. Such
antibodies are found both in patients with different inflam-
matory diseases and in healthy individuals, indicating that
shared epitopes between bacterial and human HSP60 may
exist [8-13]. However, studies have yet to determine the
pathogenic role for such autoantibodies and whether these
are in fact cross-reactive [14].
SpA comprises a heterogeneous group of immune-
mediated inflammatory diseases, which includes the bac-
teria-triggered (that is, Chlamydia trachomatis, Salmonella,
Yersenia and Campylobacter jejuni) disease reactive arthri-
tis (ReA). Even though a link to an antecedent infection is
less clear for the other forms of SpA diseases [15], the
group shares clinical, pathological and genetic features, and
especially the link to human leukocyte antigen B27 (HLA-
B27) is well-documented [16]. However, knowledge about
how HLA-B27 may contribute to disease development is
missing [17]. Moreover, the frequency of the HLA-B27
genotype varies in the different SpA diseases [16].
The most significant results revealing the importance of
the host-pathogen interaction in SpA disease came from
studies done in rodents [18]. Such studies demonstrated
that HLA-B27-transgenic rats do not develop inflamma-
tory pathology in the intestine or the joints as long as they
are kept in a germ-free environment [19]. Human studies
include transfection of human cell lines with HLA-B27
and investigation of a possible interaction with pathogenic
arthritis-related bacteria through changes in cytokine pro-
files, T-cell responses or HLA-B27 expression. However,
results from these studies seem to differ, depending on the
investigated pathogens [20-22]. As in ReA, autoimmunity
against HSP60 has also been speculated as a trigger
mechanism in SpA disease development, but such studies
are few, and often the patient material was split up into
disease subgroups [13,23,24]. In addition, existing serologi-
cal analyses targeting arthritis-related bacterial HSP60 in
SpA patients were without subclass specificity and follow-
up [13,23,24]. Furthermore, in these studies, it was not
clear whether the purification method of the HSP60 anti-
gens retained the in vivo conformation. Improvements of
these parameters would increase not only the specificity in
the IgG response but also the analysis of cross-reactivity
and the ability to determine whether such antibodies are
of importance in SpA pathogenesis. Recently, a serology
study on females diagnosed with tubal factor infertility
(TFI) was performed, and it was shown by ELISA that IgG
antibodies to C. trachomatis HSP60 were of the IgG1 and
IgG3 subclass and that no antibodies against human
HSP60 could be detected [25]. In that study, it was
demonstrated that determination of IgG1 subclass antibo-
dies to chlamydial HSP60 increased the diagnostic value of
the ELISA in identifying TFI.
Therefore, we adopted this approach and performed a
study to analyze the quantified serum levels of IgG sub-
class antibodies to native bacterial and human HSP60 in
a cohort of well-characterized SpA patients compared
with an age- and gender-matched control group. We
evaluated the association between antibody levels and
disease severity assessed by clinical scoring comprising
the Bath Ankylosing Spondylitis Metrology Index
(BASMI), Bath Ankylosing Spondylitis Functional Index
(BASFI), Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) and MRI changes in the spine and
sacroiliac joints (SIJs) in addition to HLA-B27 status.
Materials and methods
Patients and healthy controls
The study included two serum samples from SpA
patients (n = 39) with symptoms restricted to the axial
skeleton. Serum samples were collected from 2004
through 2006 and again in 2010 and 2011. At each point
in time, clinical, radiological and MRI measurements
were performed [26,27]. The clinical scorings comprised
BASMI, BASFI and BASDAI. In addition C-reactive pro-
tein (CRP) concentration and the HLA-B27 status were
determined. At the time of study entry, the examination
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included serum sampling and MRI of the SIJ and the
spine, which was scored according to the Danish system
[26,27]. All patients met the European Spondyloarthropa-
thy Study Group (ESSG) and the Assessment of Spondy-
loArthritis international Society (ASAS) criteria [28,29].
Serum samples were collected from age- and gender-
matched healthy volunteers (n = 39) in 2010 and served
as controls. The characteristics of the patients and
healthy controls are given in Table 1.
The patients were enrolled from the outpatient clinic
at Aarhus University Hospital after they gave their
informed, written consent according to the Danish Data
Protection Agency, the Regional Ethics Committee of
Central Jutland, Denmark (project numbers 20050046
and 20100083), and the Declaration of Helsinki.
Characteristics of the patients
There was no significant difference between SpA and the
control group regarding age and gender, whereas the num-
ber of HLA-B27-positive persons was higher in the patient
group (54%) than in the control group (8% in Caucasians)
(Table 1) [30]. The duration of the disease was, on average,
8 years when the first blood sample was drawn. Most of
the patients (n = 36) did not receive any treatment at the
time of enrollment in the study (Table 1). C-reactive pro-
tein (CRP) was within the normal range at both time points
(Table 1). All patients showed signs of inflammation on
MRI, with decreased activity over time.
Cloning and purification of recombinant HSP60
Escherichia coli clones containing the genes encoding
full-length human HSP60 and C. trachomatis HSP60
were obtained from Loke Diagnostics (Risskov,
Denmark). C. jejuni and S. enterica Enteritidis HSP60
genes were cloned in pET30ek-LIC vector (Invitrogen,
Carlsbad, CA). The C. jejuni HSP60 gene was amplified
with the forward primer GACGACGACAAGATGGCA
AAAGAAATTATTTTTTCAGATGAAGC and reverse
primer GAGGAGAAGCCCGGTTTACATCATTCCT
CCCATGCC. For the S. enterica Enteritidis HSP60
gene, the forward primer GACGACGACAAGATGG-
CAGCTAAAGACGTAA-AATTCGG and reverse pri-
mer GAGGAGAAGCCCGGTTTACATCATGCCGCCC
were used. The PCR products were cloned into pET30ek-
LIC by ligase-independent cloning according to the manu-
facturer’s instructions (Novagen; Merck KGaA, Darmstadt,
Germany).
The HSP60 proteins were expressed in E. coli BL21
(DE3) using 1 mM isopropyl-b-D-thiogalactopyranoside
(IPGT) for 2 h. A sample was removed from a 500-ml
bacterial culture before and after induction and analyzed
by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) [31].
The recombinant HSP60 proteins for ELISA were puri-
fied by Ni2+ affinity chromatography under non-denaturing
condition using an imidazole step gradient for passing
through a Hi-Trap column (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden) as described by Schmitt et al. [32].
Fractions that contained protein were pooled together into
separate Spectra/Por 1 membrane bags (Spectrum Labora-
tories Europe, Breda, The Netherlands) and dialyzed against
PBS with EDTA (1 mM) for 20 h. Endotoxin levels of puri-
fied protein were measured using Limulus Amebocyte
Lysate (LAL) QCL-1000 according to ‘the manufacturer’s
Table 1 Characteristics of SpA patients and healthy controls
Characteristics SpA patients (n = 39) HCs (n = 39)
2006 2010
Mean age, yr 38 (23-49) 42 (27-53) 37 (23-58)
Gender, % females 56 - 64
HLA-B27-positive, % 54 - ND
Disease duration, mean, years 8 (3-19) ND 0
Anti-TNF treatment 3 6
Average MRI activity score
SIJ 4.8 (2.0-2.1) 2.5 (0.4-6.3) ND
Spine 2.0 (0.0-3.3) 1.0 (0.0-2.0) ND
Average MRI chronicity score
SIJ 12.0 (3.0-27.8) 17.8 (3.0-31.5) ND
Spine 0.0 (0.0-4.0) 1.0 (0.0-5.5) ND
CRP (normal <8 mg/L) 1.89 (1.26-3.36) 1.3 (0.5-2.55) ND
BASDAI 32 (14-53) 28 (15-50) ND
BASMI 0 (0-40) 0 (0-10) ND
BASFI 18 (6-33) 14 (8-34) ND
SpA: spondyloarthritis, HC: healthy control, ND: not done, NT: no treatment, CRP: C-reactive protein, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index,
BASMI: Bath Ankylosing Spondylitis Metrology Index, BASFI: Bath Ankylosing Functional Index, MRI: magnetic resonance imaging, SIJ: sacroiliac joint. Data are
shown as medians (if not stated otherwise) with interquatile ranges (IQRs).
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instructions (Lonza, Basel, Switzerland). None of the puri-
fied samples exceeded 5 EU/mg protein.
The purified HSP60 proteins and the total protein
content of induced protein from E. coli BL21 (DE3)
were analyzed by 10% SDS-PAGE [31]. To determine
the molecular size of the recombinant protein, Mark 12
(Invitrogen Life Technologies, Carlsbad, CA, USA) was
used.
Enzyme-linked immunosorbent assay (ELISA)
The prevalence of antibodies was determined by ELISA
using subclass-specific secondary antibodies. The ELISA
was performed as described by Hjelholt et al. [25] and
Drasbek et al. [33]. ELISA plates were coated with 4 μg/ml
human HSP60, C. trachomatis HSP60, C. jejuni HSP60 or
S. enterica Enteritidis HSP60. The human serum samples
were diluted 1:50 in BAC-DIL (medac, Hamburg, Ger-
many) before use. The secondary anti-human IgG antibo-
dies used were conjugated horseradish peroxidase (HRP),
sheep anti-human IgG1, IgG2, IgG3 and IgG4 (Binding
Site, Birmingham, UK), diluted in BAC-DIL. The dilutions
were chosen so that the 450-nm optical density (OD450)
levels were localized on the linear portion of the standard
curve. For quantification of IgG subclass antibodies,
NUNC MaxiSorp plates were coated with dilution series
of native IgG1, IgG2, IgG3 and IgG4 from human mye-
loma plasma (EMD Biosciences, San Diego, CA, USA) in
carbonate coating buffer (50 mM NaHCO3, pH 9.6). The
ELISA was performed using the respective secondary
antibodies.
All samples were measured in duplicate. To diminish
intra-assay variation, serum samples from each patient
were measured next to each other on the ELISA plate.
Each plate had a positive and negative control included to
diminish interassay variation. In this study, intra- and inter-
assay variability was less than 10% and 5%, respectively.
OD was read with a Tecan Sunrise reader at 450 nm and
620 nm as a reference length, and the ELISA results were
analyzed using Magellan Data Analysis Software (Tecan,
Männedorf, Switzerland). The C. trachomatis-IgG-ELISA-
plus plate (medac) [34] were used for the major outer
membrane protein peptide-based analysis, and the C. pneu-
moniae-IgG-ELISA-plus plate (medac) was used to deter-
mine IgG subclass antibodies to C. pneumoniae (medac).
Statistical analysis
The data were analyzed using GraphPad Prism version
5.0a software for Mac OS × (GraphPad Software Inc., La
Jolla, CA, USA). The Shapiro-Wilk normality test was
performed to reject normally distributed data (a = 0.05,
P < 0.0001). The Mann-Whitney rank-sum test was
used to compare differences between antibody levels in
different groups. The Wilcoxon matched-pairs test for
paired samples was used to compare differences between
antibody levels in paired samples. The Spearman non-
parametric correlation coefficient was used to analyze
the correlation between antibody levels, as well as
between antibody levels and the score values from BAS-
DAI, BASFI, BASMI and for activity and chronic SpA
changes by MRI. P < 0.01 was considered statistically
significant. The confidence interval used was 99%.
Results
Purification of recombinant HSP60 and optimization of
ELISA
A multiple sequence alignment of the linear amino acid
sequence of the HSP60 proteins from S. enterica Enteriti-
dis, C. jejuni, C. trachomatis and C. pneumoniae and from
human HSP60 are shown in Figure 1. Stars above and bars
underneath the sequences mark identical amino acids.
C. trachomatis HSP60 shares more than 90% identity with
Chlamydia spp., 60% identity with other bacteria and 50%
identity with human HSP60 [35]. This comparison, which
reflects the linear sequence, is important because mea-
sured antibodies targeting bacterial HSP60 have been pro-
posed to cross-react with the human homolog and elicit
the autoimmune reaction seen in bacteria-triggered arthri-
tis [9,10,13]. To increase antibody specificity and assay
sensitivity, we purified the HSP60 antigens in their native
form, leaving out denaturants in the preparation of the
recombinant protein or as part of the elution buffer [32].
Instead, the elution buffer consisted of imidazole at non-
denaturing concentrations, which is passed through the
column as a step gradient. The excess of imidazole dis-
places the His tag from the nickel column, freeing the His-
tagged proteins. Induction and purity of the eluted HSP60
protein was analyzed by SDS-PAGE, as shown in Figure 2.
The total protein content from the uninduced (-IPTG;
lanes D, G, J and M) and induced (+IPTG; lanes C, F, I
and L) samples was analyzed by SDS-PAGE next to the
purified HSP60 proteins (lanes B, E, H and K). Induced
and purified proteins were of similar size (Figure 2).
The optimization of the ELISA was done to obtain the
optimal dynamic range of the measured antibodies using
a single dilution of the serum samples (1:50). To avoid
deficiency in epitopes, the antigen was used in a high
coating concentration (4 µg/ml). A strongly seropositive
serum sample was diluted 1:50 and evaluated with differ-
ent concentrations of each enzyme-conjugated IgG sub-
class antibody. The concentration of the secondary
antibody was determined from the dilution used to
obtain an OD value of 2 for this serum sample (1:10,000
for IgG1). A standard curve for IgG1 was generated by
coating an ELISA plate with dilutions of myeloma IgG1
as the antigen and reacting it with HRP-conjugated goat
anti-human IgG1 diluted 1:10,000 as shown in Figure 3.
Similarly, standard curves were made for the other sub-
class antibodies. Such curves were used to determine the
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immunoglobulin concentration (µg/ml) from the OD
values determined by ELISA.
Clinical characteristics of the SpA patients and healthy
controls
During the observation period, there was no significant
overall change in CRP, BASDAI, BASMI or BASFI; how-
ever, a tendency toward an increase in the BASDAI,
BASFI and BASMI score was observed. During the
period, 11 patients decreased and 22 patients increased
in BASDAI, 13 patients decreased and 19 patients
increased in BASFI, and 3 patients decreased and 10
patients increased in BASMI. The MRI activity score for
SIJ decreased significantly (P = 0.0001), whereas the
                          **:: :. :**  : .**. * :** **:**:** *::::*:*:* :*****:**:.::* *. :*:**.:*::**.:: : ************.:* .**:. :: * **::::**:  *  .
S. enterica Enteritidis HSP60 ------------------------MAAKDVKFGNDARVKMLRGVNVLADAVKVTLGPKGRNVVLDKSFGAPTITKDGVSVAREIELEDKFENMGAQMVKEVASKANDAAGDGTTTATVLAQSIITEGLKAVAAGMNPMDLKRGIDKAVAA   150
C. jejuni HSP60 -------------------------MAKEIIFSDEARNKLYEGVKKLNDAVKVTMGPRGRNVLIQKSFGAPSITKDGVSVAKEVELKDSLENMGASLVREVASKTADQAGDGTTTATVLAHAIFKEGLRNITAGANPIEVKRGMDKACEA   150
C. trachomatis D HSP60 ------------------------MVAKNIKYNEEARKKIQKGVKTLAEAVKVTLGPKGRHVVIDKSFGSPQVTKDGVTVAKEVELADKHENMGAQMVKEVASKTADKAGDGTTTATVLAEAIYTEGLRNVTAGANPMDLKRGIDKAVKV   150
C. pneumoniae HSP60 ------------------------MAAKNIKYNEEARKKIHKGVKTLAEAVKVTLGPKGRHVVIDKSFGSPQVTKDGVTVAKEIELEDKHENMGAQMVKEVASKTADKAGDGTTTATVLAEAIYSEGLRNVTAGANPMDLKRGIDKAVKV   150
Human mitochondrial HSP60 MLRLPTVFRQMRPVSRVLAPHLTRAYAKDVKFGADARALMLQGVDLLADAVAVTMGPKGRTVIIEQSWGSPKVTKDGVTVAKSIDLKDKYKNIGAKLVQDVANNTNEEAGDGTTTATVLARSIAKEGFEKISKGANPVEIRRGVMLAVDA   150
 1.......10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150
                           : :::  *      : ****.*****.*  :*::*::**.***:.* ***:: . ::  *:::***:*:***:*.** ...:     :... :*: :***:.::.::*.*:      :**:****:::****:***:* ::  ..: **
S. enterica Enteritidis HSP60 AVEELKALSVPCSDSKAIAQVGTISANSDETVGKLIAEAMDKVGKEGVITVEDGTGLQDELDVVEGMQFDRGYLSPYFINKPETGAVELESPFILLADKKISNIREMLPVLEAVAKAGKPLLIIAEDVEGEALATLVVNTMRGIVKVAAV   300
C. jejuni HSP60 IVAELKKLSREVKDKKEIAQVATISANSDEKIGNLIADAMEKVGKDGVITVEEPKSINDELNVVEGMQFDRGYLSPYFITNAEKMTVELSSPYILLFDKKITNLKDLLPVLEQIQKTGKPLLIIAEDIEGEALATLVVNKLRGVLNISAV   300
C. trachomatis D HSP60 VVDQIRKISKPVQHHKEIAQVATISANNDAEIGNLIAEAMEKVGKNGSITVEEAKGFETVLDIVEGMNFNRGYLSSYFATNPETQECVLEDALVLIYDKKISGIKDFLPVLQQVAESGRPLLIIAEDIEGEALATLVVNRIRGGFRVCAV   300
C. pneumoniae HSP60 VVDELKKISKPVQHHKEIAQVATISANNDSEIGNLIAEAMEKVGKNGSITVEEAKGFETVLDVVEGMNFNRGYLSSYFSTNPETQECVLEDALILIYDKKISGIKDFLPVLQQVAESGRPLLIIAEEIEGEALATLVVNRLRAGFRVCAV   300
Human mitochondrial HSP60 VIAELKKQSKPVTTPEEIAQVATISANGDKEIGNIISDAMKKVGRKGVITVKDGKTLNDELEIIEGMKFDRGYISPYFINTSKGQKCEFQDAYVLLSEKKISSIQSIVPALEIANAHRKPLVIIAEDVDGEALSTLVLNRLKVGLQVVAV   300
                  .......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......290.......300
                           *******.**  *:*:*  *** :..** :   **..    **:.  *:: *: : ::.* *::  :: *  .*  *:  ::*:*::***:**:***:.****::**.::: *::*** ** **  ** ******:: *** **::  . 
S. enterica Enteritidis HSP60 KAPGFGDRRKAMLQDIATLTGGTVISEE-IGMELEKATLEDLGQAKRVVINKDTTTIIDGVGEEAAIQGRVAQIRQQIEEATSDYDREKLQERVAKLAGGVAVIKVGAATEVEMKEKKARVEDALHATRAAVEEGVVAGGGVALIRVASK   450
C. jejuni HSP60 KAPGFGDRRKAMLEDIAILTGGEVISEE-LGRTLESATIQDLGQASSVIIDKDNTTIVNGAGEKANIDARVNQIKAQIAETTSDYDREKLQERLAKLSGGVAVIKVGATTETEMKEKKDRVDDALSATKAAVEEGIVIGGGAALIKAKAK   450
C. trachomatis D HSP60 KAPGFGDRRKAMLEDIAILTGGQLISEE-LGMKLENANLAMLGKAKKVIVSKEDTTIVEGMGEKEALEARCESIKKQIEDSSSDYDKEKLQERLAKLSGGVAVIRVGAATEIEMKEKKDRVDDAQHATIAAVEEGILPGGGTALIRCIPT   450
C. pneumoniae HSP60 KAPGFGDRRKAMLEDIAILTGGQLVSEE-LGMKLENTTLAMLGKAKKVIVTKEDTTIVEGLGNKPDIQARCDNIKKQIEDSTSDYDKEKLQERLAKLSGGVAVIRVGAATEIEMKEKKDRVDDAQHATIAAVEEGILPGGGTALVRCIPT   450
Human mitochondrial HSP60 KAPGFGDNRKNQLKDMAIATGGAVFGEEGLTLNLEDVQPHDLGKVGEVIVTKDDAMLLKGKGDKAQIEKRIQEIIEQLDVTTSEYEKEKLNERLAKLSDGVAVLKVGGTSDVEVNEKKDRVTDALNATRAAVEEGIVLGGGCALLRCIPA   450
                  .......310.......320.......330.......340.......350.......360.......370.......380.......390.......400.......410.......420.......430.......440.......450
                           :          *: :*  :  :::  *   *. *.* : .:: : :    . : *::*    : :*:: **:**.** * **  *..:*.:: *:*  :::: :  . .      . *  .       
S. enterica Enteritidis HSP60 IA-DLKGQN-EDQNVGIKVALRAMEAPLRQIVLNCGEEPSVVANTVKGG-DGNYGYNAATEEYGNMIDMGILDPTKVTRSALQYAASVAGLMITTECMVTDLPKS-DAPDLGAAGGMGGMGGMGGMM-   578
C. jejuni HSP60 IKLDLQG----DEAIGAAIVERALRAPLRQIAENAGFDAGVVVNSVENAKDENTGFDAAKGEYVNMLESGIIDPVKVERVALLNAVSVASMLLTTEATISEIKE--DKPTMPDMSGMGGMGGMGGMM-   578
C. trachomatis D HSP60 LEAFLPMLTNEDEQIGARIVLKALSAPLKQIAANAGKEGAIIFQQVMSR-SANEGYDALRDAYTDMLEAGILDPAKVTRSALESAASVAGLLLTTEALIAEIPEE-KPAAAPAMPGAG-MDY------   578
C. pneumoniae HSP60 LEAFLPMLANEDEAIGTRIILKALTAPLKQIASNAGKEGAIICQQVLAR-SANEGYDALRDAYTDMIDAGILDPTKVTRSALESAASIAGLLLTTEALIADIPEE-KSSSAPAMPSAG-MDY------   578
Human mitochondrial HSP60 LDSLTPAN--EDQKIGIEIIKRTLKIPAMTIAKNAGVEGSLIVEKIMQS-SSEVGYDAMAGDFVNMVEKGIIDPTKVVRTALLDAAGVASLLTTAEVVVTEIPKEEKDPGMGAMGGMG--GGMGGGMF   578
                  .......460.......470.......480.......490.......500.......510.......520.......530.......540.......550.......560.......570........
MLS
Figure 1 Multiple sequence alignment of bacterial and human HSP60. A multiple sequence alignment was created with ClustalX 2.0.12
software to compare the amino acid sequences of bacterial HSP60 (Salmonella enterica Enteritidis [GenBank:YP_002246130.1], Campylobacter
jejuni [GenBank:CAA73778.1], C. trachomatis [GenBank:ADI51797.1]) and C. pneumoniae [GenBank:P31681.2]) and human HSP60 [GenBank:
NP_955472.1]. The bar diagram illustrates areas of high sequence consensus. MLS: mitochondrial leader sequence.
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Figure 2 SDS-PAGE gel of bacterial and human HSP60. Size and
purity of each recombinant protein were evaluated using 10% SDS-
PAGE gel. The different HSP60 proteins for ELISA were purified using
a Ni+ column and imidazole as a competing reagent. Vector
transformation was confirmed by isopropyl-b-D-
thiogalactopyranoside (IPGT) induction. Lane A: Molecular weight
marker. Lanes B, E, H and K: Purified HSP60. Lanes C and D, F and G,
I and J and L and M: Total protein content from Escherichia coli
strain BL21 (DE3) with (+) and without (-) IPGT induction.
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Figure 3 Standard curve for IgG1. A standard curve was made
using Magellan Data Analysis Software to quantify the A450 nm
values from ELISA. An ELISA plate was coated with a known serial
dilution (0.0625-4 µg/ml) of native IgG1 subclass from human
myeloma plasma before incubating wells with HRP-conjugated
secondary antibody. Correlation between A450 nm values and
concentration was fitted by the regression output (r = 0.99507).
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spinal MRI activity score did not change. As expected, a
slight but nonsignificant increase was present in the
MRI evaluation of both spine and SIJ regarding chroni-
city. There was a general tendency toward low disease
activity in patients at both time points. Six patients
received treatment with anti-TNF during the period of
observation (Table 1).
IgG1 and IgG3 antibodies to human and bacterial HSP60
in SpA patients and healthy controls
Individual levels of the IgG subclass antibodies to
human HSP60 (Figure 4A) and HSP60 of S. enterica
Enteritidis (Figure 4B), C. trachomatis (Figure 4C) and
C. jejuni (Figure 4D) in SpA patients and controls are
shown in Figure 4. Although IgG1 and IgG3 antibodies
were detected in serum samples of both SpA patients
and controls, no IgG2 or IgG4 antibodies were detected
for any of the four HSP60 antigens.
The levels of anti-human HSP60 for IgG1 and IgG3 are
shown in Table 2. In SpA patients, these levels are signifi-
cantly higher than those of healthy controls (Table 3).
Elevated levels of IgG1 against S. enterica Enteritidis
HSP60 were found in SpA patients compared with
healthy controls (Table 3). There were no significant dif-
ferences in IgG1 and IgG3 to C. trachomatis HSP60 and
C. jejuni HSP60 between SpA patients and healthy
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Figure 4 Antibody levels to human and bacterial HSP60 in the SpA cohort group and the control group. Serum levels (µg/ml) of IgG1
and IgG3 antibodies against (A) human HSP60, (B) Salmonella enterica Enteritidis, (C) Chlamydia trachomatis HSP60 and (D) Campylobacter jejuni
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controls (Table 3). Levels of IgG3 against human HSP60
were higher than levels of IgG1 at both time points (P <
0.001, Table 2). The highest antibody levels for IgG3
against human HSP60 were measured in 2006 (Figure 4A);
however, no significant difference in IgG1 and IgG3 levels
was found between paired samples (2006 through 2010),
respectively, for any of the investigated HSP60 antigens
(Figure 4). When the patients were divided into two
groups according to the HLA-B27 genotype, no significant
differences in antibody levels were observed between
HLA-B27-positive and HLA-B27-negative patients for any
of the investigated HSP60 antigens.
IgG1 and IgG3 antibodies to C. pneumoniae, C. trachomatis
and HSP60 from C. trachomatis
To determine whether antibodies to C. pneumoniae or
antibodies to C. trachomatis were associated with antibo-
dies to HSP60 from C. trachomatis, individual levels of IgG
antibodies (IgG1 and IgG3) against C. pneumoniae, C. tra-
chomatis and C. trachomatis HSP60 were determined in
SpA patients and healthy controls (Figure 5). A large pro-
portion of both SpA patients (IgG1 = 84.6%, detection
limit OD = 0.1) and controls (IgG1 = 76.9%, detection
limit OD = 0.1) had IgG1 antibodies against C. pneumo-
niae (Figure 5A) [36]. Levels of IgG1 antibodies against
C. pneumoniae (Table 2) were significantly higher than
levels of IgG3 antibodies (Figure 5A, P < 0.0001). Low
levels of both IgG1 and IgG3 antibodies were found against
C. trachomatis (Figure 5B) and C. trachomatis HSP60
(Figure 5C), and only a few serum samples were positive
(Figure 5B). However, a significant difference between SpA
patients and controls was observed for IgG1 antibodies
against C. trachomatis in 2006 (Figure 5B, P < 0.01; see
also Table 3). In one serum sample, high levels of IgG1
antibodies against C. trachomatis were seen both in 2006
(20.1 μg/ml) and in 2010 (49.7 μg/ml). This serum sample
also had IgG1 antibodies to C. trachomatis HSP60 (2006 =
17.7 μg/ml and 2010 = 36.4 μg/ml) and to C. pneumoniae
(2006 = 30 μg/ml and 2010 = 23.7 μg/ml), indicating an
ongoing or recent Chlamydia infection.
IgG1 and IgG3 antibodies to human HSP60 in SpA patients
To visualize the course of anti-human HSP60 IgG1 and
IgG3 over time, subclass antibody levels for the SpA
group (n = 39) were plotted and a line was drawn con-
necting the serum samples from 2006 and 2010, respec-
tively (Figures 6A and 6B). The antibody levels of IgG1
(Figure 6A) and IgG3 (Figure 6B) showed no significant
change from 2006 to 2010. Levels of IgG1 were mainly
unchanged (Figure 6A), whereas IgG3 showed both
increases and decreases (Figure 6B). Two of the serum sam-
ples had high levels of IgG3 (27.41 μg/ml and 48.65 μg/ml,
respectively) in 2006, and there was a decrease from 2006
to 2010 (Figure 6B).
A comparison of the levels of IgG1 with those of IgG3
in the same serum sample (n = 39) against human
Table 2 Medians and interquatile ranges (IQRs) of IgG1 and IgG3 antibody levels (μg/mL) against six different
antigens in the SpA group
Antigen Median (IQR)
2006 2010
IgG1 IgG3 IgG1 IgG3
Human HSP60 2.046 (1.896-2.345) 2.689 (2.476-4.827) 2.131 (1.936-2.503) 2.583 (2.455-3.475)
Salmonella enterica Enteritidis HSP60 2.635 (2.109-4.300) 2.514 (2.443-2.799) 2.660 (2.240-3.681) 2.534 (2.452-3.142)
Chlamydia trachomatis HSP60 2.123 (1.939-2.694) 2.522 (2.453-2.726) 2.096 (1.957-2.747) 2.631 (2.472-2.960)
Campylobacter jejuni HSP60 2.459 (2.347-2.640) 2.447 (2.403-2.628) 2.496 (2.395-2.622) 2.462 (2.409-2.684)
Chlamydia pneumoniae 7.965 (2.807-24.56) 2.397 (2.397-2.730) 8.953 (2.839-21.75) 2.450 (2.397-2.777)
Chlamydia trachomatis 2.082 (2.052-2.174) 2.416 (2.406-2.473) 2.103 (2.065-2.216) 2.421 (2.410-2.491)
Table 3 Statistical differences in IgG1 or IgG3 levels between SpA patients (n = 39) and healthy controls (n = 39)
against six different antigens
Antigen IgG1 IgG3
2006 2010 2006 2010
Human HSP60 0.0082** 0.0004*** 0.0001*** 0.0022**
Salmonella enterica Enteritidis HSP60 0.0008*** 0.0002*** 0.8455 0.2782
Chlamydia trachomatis HSP60 0.9164 0.7453 0.0932 0.8338
Campylobacter jejuni HSP60 0.0451 0.1109 0.9482 0.5587
Chlamydia pneumoniae 0.3738 0.4211 0.0892 0.3748
Chlamydia trachomatis 0.0089** 0.0786 0.2693 0.4010
SpA: spondyloarthritis, HC: healthy control. The Mann-Whitney rank-sum test was used to compare the SpA cohort group (2006 and 2010) with healthy controls.
Ig, immunoglobulin. ***P < 0. 001. **P < 0.01.
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HSP60 from 2006 showed a trend toward an inverse
correlation (r = -0.2). In the serum samples taken in
2010, a similar inverse correlation (r = -0.054) was
observed, and it was more distinct at high IgG subclass
levels (Figures 6C and 6D).
Investigation of cross-reactive antibodies in SpA patients
To compare the IgG subclass levels, lines were drawn
between IgG1 of human HSP60 and IgG1 of HSP60 from
S. enterica Enteritidis, C. trachomatis and C. jejuni
(Figures 7A-7C). Samples with high levels of IgG1 antibo-
dies against human HSP60 tended to show low levels of
IgG1 against bacterial HSP60 and vice versa (Figures 7A-
7C). A similar trend was observed for IgG3 antibodies
(Figures 7D-7F), with the exception of one serum sample
positive for S. enterica Enteritidis (Figure 7E). This obser-
vation suggests that antibodies to human HSP60 develop
independently of antibodies to bacterial HSP60, even
though antibodies to a single bacterial HSP60 frequently
were seen in serum samples from these individual patients.
No significant correlation was observed between the two
subclass antibodies against any of the bacterial HSP60 or
human HSP60 (P > 0.01), which is in agreement with the
negative correlation observed between IgG1 and IgG3
antibodies against human HSP60, and thus we observed
no cross-reaction between human and microbial HSP60.
However, correlations between IgG1 and IgG3, respec-
tively, against the three bacterial HSP60 were observed
(data not shown). The strongest correlation was between
IgG1 against HSP60 from S. enterica Enteritidis and
C. jejuni in 2006 (r = 0.7, P < 0.001), which is in agreement
with their higher amino acid sequence identity (Figure 1).
IgG1 and IgG3 anti-HSP60 related to disease severity
No significant correlation was found between the pre-
sence of antibodies to either human or bacterial HSP60
and age, sex, treatment, CRP, MRI scores, HLA-B27 and
any of the BAS indexes (P > 0.01). The change in anti-
body levels compared with change in BAS indexes and
MRI change from 2006 to 2010 also did not show any
correlation (P > 0.01).
Discussion
In the present study, we investigated the hypothesis of
molecular mimicry as a pathogenic trigger in axial SpA.
Potential cross-reaction regions were visualized in an
alignment of the amino acid sequences of human and
bacterial HSP60, which showed five regions with five to
eight identical amino acid residues for all of the investi-
gated HSP60 proteins, indicating the presence of poten-
tial epitopes (Figure 1). However, these protein regions
may not represent epitopes for infection-induced antibo-
dies, as most antibodies recognize conformational epi-
topes presented in the three-dimensional shape of the
protein [37], and, even if cross-reactive antibodies were
present, it would not prove causation of disease. There-
fore, due to the lack of similar studies that include ana-
lysis of IgG subclass response to bacterial and human
HSP60, this hypothesis is a target for further analysis
[11,23,24,38].
In our study, we found elevated levels of both IgG1
and IgG3 antibodies to human HSP60, indicating an
increased autoimmune activity in the 39 axial SpA
patients (Figure 4A). We found no correlations of IgG
antibodies between bacterial and human HSP60, and
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Figure 5 Antibody levels to Chlamydia pneumoniae, C. trachomatis and C. trachomatis HSP60 in the SpA cohort and the control group. Serum
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there was no general elevation in levels of antibodies to
bacterial HSP60 (Figures 4B-4D). In the present study,
generation of antibodies to human HSP60 was indepen-
dent of the presence of antibodies to bacterial HSP60,
and cross-reactivity was not found (Figure 7). In addi-
tion, different subclasses (that is, IgG1 and IgG3) were
found to be predominant in the antibody response to
bacterial and human HSP60, thus strengthening the
ability of the humoral immune response to maintain its
specificity, even between similar antigenic molecules.
A significant elevation in levels of IgG1 antibodies
against HSP60 from S. enterica Enteritidis, but not from
C. jejuni and C. trachomatis, was also observed in the
group of SpA patients compared with the control group
(Figure 4). These findings suggest that more SpA
patients have had an infection with Salmonella than
with an infection with C. trachomatis or C. jejuni. They
are in agreement with a high incidence in S. enterica
Enteritidis infections in Denmark that increased from
1997 to 1999 [39]. The observation that a higher num-
ber of patients are positive for S. enterica Enteritidis
than for C. trachomatis (Figures 4B, 5B and 5C) could
be explained by the overweight of females (56%, Table
1), as postdysentery ReA is equally common in males
and females, whereas postchlamydial ReA is much more
common in males [40].
To investigate the IgG subclass response against bacter-
ial antigens, we determined the IgG subclass response to
C. pneumoniae and C. trachomatis (Figure 5). We found
that the IgG antibody response against C. pneumoniae was
of the IgG1 subclass (Figure 5A). Thus, the production of
IgG3 antibodies was not a general response to bacterial
antigens in SpA patients. Furthermore, as recently sug-
gested by Carter et al., a previous infection with C. pneu-
moniae may be associated with SpA [41]. We therefore
evaluated the association between the SpA disease and
levels of antibodies to C. pneumoniae [34]. However, there
was no statistical difference in the IgG1 antibody levels of
SpA patients and controls. In 1999, Hannu et al. used
microimmunofluorescence microscopy to detect antibo-
dies to C. pneumoniae, and they found that 4 (approxi-
mately 10%) of 35 patients with ReA were highly positive.
Of these four patients, three had had lower respiratory
tract infection prior to the development of ReA, indicating
a possible trigger of the disease [42]. We found that 84%
of the SpA patients and 76.9% of controls had IgG1 anti-
bodies to C. pneumoniae, but such antibodies were not
correlated with the presence of chlamydial HSP60 antibo-
dies. This finding indicates that a C. pneumoniae infection
does not trigger production of antibodies to chlamydial
HSP60, even though HSP60 of C. pneumoniae is highly
similar to HSP60 of C. trachomatis (90%, Figure 1). This is
in contrast to what was found when serum from TFI
patients was analyzed for the presence of subclass antibo-
dies [25]. Antibodies to both C. trachomatis and to C. tra-
chomatis HSP60 were found in serum from TFI patients.
However, although antibodies to chlamydial HSP60 were
primarily IgG1, antibodies to C. trachomatis were predo-
minantly IgG3. None of the TFI patients had antibodies
to human HSP60, indicating that in this study no cross-
reactive antibodies between human and bacterial HSP60
were found [25].
IgG1 and IgG3 have similar properties in terms of
activating complement and binding of Fc receptors [43].
This may explain why they are often induced together,
indicating a shared switch mechanism (via IL-21 stimu-
lation), as reported by Péne et al. [44]. However, on the
basis of the results of the present study, IgG3 was the
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predominant antibody subclass to human HSP60.
Furthermore, a trend toward an inverse association
between IgG1 and IgG3 antibodies to this antigen was
seen (Figures 6C and 6D), indicating the presence of a
fine-tuning mechanism, recently suggested to be IL-4
[45]. A study similar to ours showed the same distribu-
tion of the IgG subclass response to a self-antigen, pep-
tidylarginine deiminase 4 (PADI4), in patients with
rheumatoid arthritis (RA) [46]. However, in this study,
the dominant subclass was IgG1 and not IgG3. The
structure of the two molecules differs in that IgG3 is
more flexible due to its longer hinge region [47]. They
also differ in half-life (1 wk for IgG3 compared to 3 wk
for IgG1), and their concentrations in serum vary (65%
for IgG1 and 7% for IgG3) [48-50]. The presence of
antibodies with a short half-life, as demonstrated in this
study, indicates that the IgG3 antibodies against human
HSP60 are continuously stimulated and produced. Thus,
as suggested in other studies [51,52], the response to
human HSP60 seen in SpA patients (Figure 4A) seems to
rely on the ability to quickly control and regulate this
response. This may explain the decrease in high-level IgG3
against human HSP60 from 2006 to 2010 (Figure 6B) and
the average decrease in disease parameters (Table 1). Both
human HSP60 and PAD4I are found to be expressed in
the synovium, and PAD4I is suggested to form complexes
that activate complement proteins, thereby giving rise to
the observed correlation between the detection of the pro-
tein and the intensity of tissue inflammation in RA [53].
Autoantibodies to human HSP60 may represent a response
to a foreign extracellular antigen (that is, mitochondrial
HSP60) arising from the ongoing inflammation in the
synovial membranes. However, we found no correlation of
the antibodies against bacterial and human HSP60 to any
of the clinical parameters and MRI scores. Our SpA
patients had, in general, low disease activity but a high
level of HSP60 antibodies, suggesting that such antibodies
did not reflect the disease activity. Nor was there any rela-
tion to disease progression in clinical, and MRI scores
during the 4-yr observation period. In the present study,
HLA-B27 status did not further explain the role of anti-
human HSP60, as these antibodies were at the same level
in HLA-B27-positive and HLA-B27-negative patients. This
is in contrast to findings from a similar study by Domin-
guez-López et al., who investigated the total IgG (total)
response to enterobacterial HSP60 in ankylosing spondyli-
tis patients, one of the five disease entities defined within
SpA [23]. They found that HLA-B27-positive patients and
their healthy relatives had significantly higher IgG antibody
levels to all enterobacterial HSP60 proteins than HLA-B27-
negative healthy individuals. Furthermore, a correlation
between IgG antibodies to E. coli and Shigella flexneri
HSP60 and disease activity was observed in a later study
[24]. In these studies, antibodies to human HSP60 were
not determined, and patient disease characteristics were
not included; therefore, the results cannot be directly com-
pared to those in our study. It should be emphasized that
in our study all patients analyzed had axial disease, which
does not exclude subjects with concomitant peripheral dis-
ease, but it excludes those with only peripheral disease.
Therefore data could be different in patients with periph-
eral SpA.
In summary, we found that IgG3 antibodies against
human HSP60 were elevated in SpA patients and that
such antibodies with a short half-life were present at
both time points separated by more than 4 yr. Therefore,
IgG3 against human HSP60 must be produced constantly
in these patients, indicating a disease-related function.
However, the antibodies were not cross-reactive to bac-
terial HSP60, indicating that bacteria do not seem to be
involved at this stage of disease. Instead, we suggest that
the autoantibodies to human HSP60 represent a response
to a foreign extracellular antigen (that is, mitochondrial
HSP60) arising from the ongoing inflammation in the
synovial membranes of these axial SpA patients.
Conclusions
In a cohort of SpA patients with symptoms restricted to
the axial skeleton, elevated levels of IgG1 and IgG3 anti-
bodies to human HSP60 were determined by ELISA.
These levels were significantly higher than those in a
healthy control group of similar size matched for sex
and age. Change in antibody levels differed for IgG1 and
IgG3 over time, and there was an inverse relationship of
IgG1 to IgG3 antibodies in the sera of the SpA patients.
Generation of antibodies to human HSP60 was indepen-
dent of the presence of antibodies to bacterial HSP60,
and cross-reactivity could not be supported from the
present study. Finally, we found no evidence that HSP60
antibodies reflected the disease activity in these 39 SpA
patients.
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